Company: H. Lundbeck A/S
Headquarters: Copenhagen, Denmark
Founded: 1915
Ticker: LUN.CO (OMX Copenhagen)
Employees: ~5,500
Revenue: ~14.5 billion DKK (2023)
H. Lundbeck A/S (commonly known as Lundbeck) is a Danish multinational pharmaceutical company headquartered in Copenhagen, Denmark. Founded in 1915, Lundbeck has evolved into a focused neurosciences company dedicated to improving the lives of people with psychiatric and neurological disorders. The company is one of the few "pure-play" neuroscience companies globally, with a research portfolio concentrated entirely on brain diseases including [Alzheimer's disease, [Parkinson's disease, depression, and schizophrenia[1].
Lundbeck operates in approximately 50 countries and has R&D facilities in Denmark, the United States, and the United Kingdom. The company's strategic focus on CNS (central nervous system) disorders positions it uniquely in an industry where most large pharmaceutical companies have reduced their neuroscience investments[2].
Lundbeck's research and development concentrates on several key therapeutic areas:
| Area | Focus | Programs |
|---|---|---|
| Alzheimer's disease Disease | Amyloid/tau targeting, neuroinflammation | Lu AF20513 (vaccine), PDE4B inhibitors |
| Parkinson's disease Disease | Alpha-synuclein, dopamine pathways | Lu AG06466, D1 agonists |
| Depression | Glutamate signaling, GABA modulation | Vortioxetine derivatives, FMR |
| Schizophrenia | Dopamine/serotonin modulation | Lu AF20071 |
Lu AF20513 is an investigational [Alzheimer's disease vaccine designed to stimulate the immune system to produce antibodies against amyloid-beta plaques:
Lundbeck is developing phosphodiesterase 4B (PDE4B) inhibitors for [Alzheimer's disease:
Lundbeck has developed a bispecific antibody brain shuttle platform in partnership with Genentech (Roche) to overcome the blood-brain barrier challenge and enable delivery of therapeutic antibodies to CNS targets[3].
Platform Mechanism:
The brain shuttle technology uses bispecific antibodies that:
Key Programs:
| Product | Indication | Target | Development Stage | Notes |
|---|---|---|---|---|
| Lu AG09222 | Migraine prevention | PACAP38/TfR | Phase 1 completed (2023) | First brain shuttle program |
| Lu AF20513 | Alzheimer's disease | Amyloid/TfR | Preclinical/Phase 1 | Bispecific anti-amyloid |
| Lu AF87908 | Alzheimer's disease | Tau/TfR | Phase 1 | Anti-tau bispecific |
Partnership with Genentech:
The collaboration with Genentech combines Lundbeck's neuroscience expertise with Genentech's antibody engineering capabilities to develop next-generation bispecific antibodies for CNS disorders[4].
Clinical Data:
| Product | Indication | Development Stage | Notes |
|---|---|---|---|
| Lu AF20513 | Alzheimer's disease | Phase 1 | Amyloid vaccine, brain shuttle |
| Lu AF87908 | Alzheimer's disease | Phase 1 | Tau brain shuttle bispecific |
| Lu AG09222 | Migraine | Phase 1 | PACAP38/TfR brain shuttle |
| Lu AG06466 | Parkinson's disease | Phase 1 | Alpha-synuclein modulator |
| Droxidopa (Northera) | Neurogenic orthostatic hypotension | Approved (FDA) | Acquired from NeuroMedix |
| FMR | Depression | Phase 2 | Fast-acting glutamate modulator |
| Lu AF20071 | Schizophrenia | Phase 1 | Dopamine-serotonin modulator |
Lundbeck acquired droxidopa (brand name Northera) from NeuroMedix in 2016, expanding their Parkinson's disease portfolio to include treatment for autonomic dysfunction. Droxidopa is an FDA-approved norepinephrine prodrug indicated for the treatment of symptomatic neurogenic orthostatic hypotension (nOH)[5].
Mechanism of Action:
Clinical Profile:
Market Context:
Lundbeck's commercial portfolio includes treatments for psychiatric and neurological disorders:
| Product | Indication | Mechanism |
|---|---|---|
| Cipramil/Celexa | Depression | SSRI |
| Escitalopram | Depression/anxiety | SSRI |
| Brintellix/Trintellix | Depression | Multimodal serotonin modulator |
| Abilify Maintena | Schizophrenia/bipolar | Dopamine partial agonist |
| Ongentys | Parkinson's disease Disease | COMT inhibitor |
| Aubagio | Multiple Sclerosis | Immunomodulator (licensed from Sanofi) |
Lundbeck's strategy centers on becoming a leader in specialized neuroscience:
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue (DKK) | 14.5B | 15.7B | 17.2B |
| R&D Investment | ~3.0B | ~2.9B | ~2.8B |
| Operating Margin | ~15% | ~18% | ~22% |